Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - MGI Pharma, Inc. (NasdaqNM:MOGN)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Location
5775 West Old Shakopee Road, Suite 100
Bloomington, MN 55437
Phone: (952) 346-4700
Fax: (952) 346-4800
Email: wbrown@mgipharma.com
Employees (last reported count): 133
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Index Membership
 ·S&P 600 SmallCap
Ownership
·Insider and 5%+ Owners: 10%
·Over the last 6 months:
 · 2 insider buys; 21.0K shares (1.0% of insider shares)
·Institutional: 31% (35% of float)
(133 institutions)
·Net Inst. Buying: 1.65M shares (+20.18%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
MGI Pharma, Inc. is an oncology-focused pharmaceutical company that acquires, develops and commercializes proprietary pharmaceutical products that meet patient needs. The Company markets four cancer-related products in the United States. Salagen Tablets treats symptoms of radiation-induced xerostomia, known as chronic dry mouth, in head and neck cancer patients, and to rheumatologists as a treatment for the xerostomia associated with the autoimmune disease Sjogren's syndrome. The Company also sells Didronel I.V. Infusion, which is approved for the treatment of elevated blood calcium in late-stage cancer patients. The Company distributes Hexalen Capsules, a second-line chemotherapy for ovarian cancer patients who are refractory, or unresponsive, to existing cancer therapies. MGI also began direct promotion of Hexalen Capsules and Mylocel Tablets, a treatment for certain malignancies.
More from Market Guide: Expanded Business Description

Financial Summary
MOGN is a human pharmaceutical company that acquires, develops and markets differentiated, specialty pharmaceutical products. MOGN currently promotes products with uses in oncology and rheumatology. For the six months ended 6/30/01, total revenues rose 49% to $18.6 million. Net loss before acct. change totalled $18.5 million, vs. an income of $408 thousand. Results reflect increased demand and prices for Salagen Tablets, offset by sales force expansion and higher R and D expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Charles Blitzer, 60
Pres, CEO, Director
$580K$330K
William Brown, 45
CFO, Sec.
257K66K
Leon Moulder, Jr., 43
Exec. VP
300K--  
John MacDonald, 47
Sr. VP, R&D
--  --  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:MOGNAs of 31-Aug-2001
Price and Volume
52-Week Low
on 16-Mar-2001
$7.50 
Recent Price$11.90 
52-Week High
on 1-Sep-2000
$35.00 
Beta1.13 
Daily Volume (3-month avg)111.5K
Daily Volume (10-day avg)72.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-65.2%
52-Week Change
relative to S&P500
-53.3%
Share-Related Items
Market Capitalization$249.9M
Shares Outstanding21.0M
Float18.9M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$1.97 
Earnings (ttm)-$1.62 
Earnings (mrq)-$0.81 
Sales (ttm)$1.79 
Cash (mrq)$1.76 
Valuation Ratios
Price/Book (mrq)6.05 
Price/EarningsN/A 
Price/Sales (ttm)6.64 
Income Statements
Sales (ttm)$31.3M
EBITDA (ttm)-$30.3M
Income available to common (ttm)-$29.0M
Profitability
Profit Margin (ttm)-92.5%
Operating Margin (ttm)-98.9%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-53.47%
Return on Equity (ttm)-88.06%
Financial Strength
Current Ratio (mrq)3.84 
Debt/Equity (mrq)0 
Total Cash (mrq)$36.7M
Short Interest
As of 8-Aug-2001
Shares Short348.0K
Percent of Float1.8%
Shares Short
(Prior Month)
273.0K
Short Ratio4.14 
Daily Volume84.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.